81 / 84
81
treatment with etanercept. Arthritis Rheum
2008;58:1324-31.
60. Braun J, Baraliakos X, Listing J, Sieper J.
Decreased incidence of anterior uveitis in patients
with ankylosing spondylitis treated with the anti-
tumor necrosis factor agents infliximab and
etanercept. Arthritis Rheum 2005;52:2447-51.
61. Rudwaleit M, Rødevand E, Holck P, Vanhoof J,
Kron M, Kary S, et al. Adalimumab effectively
reduces the rate of anterior uveitis flares in patients
with active ankylosing spondylitis: results of a
prospective open-label study. Ann Rheum Dis
2009;68:696-701.
62. Braun J, Baraliakos X, Listing J, Davis J, van der
Heijde D, Haibel H, et al. Differences in the
incidence of flares or new onset of inflammatory
bowel diseases in patients with ankylosing
spondylitis exposed to therapy with anti-tumor
necrosis factor alpha agents. Arthritis Rheum
2007;57:639-47.
63. Wendling D, Balblanc JC, Briançon D, Brousse A,
Lohse A, Deprez P, et al. Onset or exacerbation of
cutaneous psoriasis during TNFalpha antagonist
therapy. Joint Bone Spine 2008;75:315-8.
64. Briot K, Gossec L, Kolta S, Dougados M, Roux C.
Prospective assessment of body weight, body
composition, and bone density changes in patients
with spondyloarthropathy receiving anti-tumor